製品名:N-Carbamimidoylacetamide

IUPAC Name:N-carbamimidoylacetamide

CAS番号:5699-40-1
分子式:C3H7N3O
純度:97%
カタログ番号:CM253718
分子量:101.11

包装単位 有効在庫 価格(USD) 数量
CM253718-100g in stock ƛƥƛ
CM253718-500g in stock ȐƥǶ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:5699-40-1
分子式:C3H7N3O
融点:-
SMILESコード:CC(=O)NC(N)=N
密度:
カタログ番号:CM253718
分子量:101.11
沸点:
MDL番号:MFCD00075615
保管方法:Keep in dark place, store at 2-8°C.

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Monlunabant
Obesity is linked to overactivity of the endocannabinoid system that regulates appetite, fat storage, and insulin resistance. Cannabinoid receptor type-1 (CB1) belongs to the G protein-coupled receptor (GPCR) superfamily, and are found in the brain and peripheral tissues. Pharmacological blockers of CB1 receptors have demonstrated effectiveness in suppressing appetite, inducing weight loss, enhancing energy expenditure and speeding up metabolism.
Novo Nordisk’s Monlunabant is a novel peripherally-acting CB1 receptor blocker. This target limits brain penetration and minimizes psychiatric side-effects. Monlunabant is developed for the treatment of metabolic disorders. The phase 2 trials for diabetic kidney disease and obesity is expected in the second half of 2024.

Related Products